OncoLize
OncoLize is a Dutch-based company specializing in high-performance oncology products for localized and slow drug delivery directly inside tumors. Their mission is to improve tumor eradication, reduce side effects, and make treatments accessible and affordable for all. They develop innovative polymer-based hydrogel platforms, such as ChemoGellTM, for safe, scalable, and affordable drug formulations, aiming to treat aggressive tumor diseases like pancreatic, lung, and other solid tumors. The company is engaged in clinical trials, patent development, and collaborations to advance cancer treatment options globally.
Industries
Nr. of Employees
small (1-50)
Products
Injectable in situ-forming hydrogel drug depot (platform)
A thermo-reversible, bio-erodible hydrogel formulation intended for injection into solid tumors where it forms a localized depot that slowly releases entrapped anti-cancer drugs over days to weeks.
ChemoGell
Thermo-responsive hydrogel drug delivery platform that transforms into a local, bio-erodible drug depot upon intratumoral injection for sustained, localized release of oncology drugs.
ChemGem
An intratumoral gemcitabine depot combining the ChemoGell platform with the standard-of-care drug gemcitabine to treat pancreatic cancer (PDAC).
Injectable in situ-forming hydrogel drug depot (platform)
A thermo-reversible, bio-erodible hydrogel formulation intended for injection into solid tumors where it forms a localized depot that slowly releases entrapped anti-cancer drugs over days to weeks.
ChemoGell
Thermo-responsive hydrogel drug delivery platform that transforms into a local, bio-erodible drug depot upon intratumoral injection for sustained, localized release of oncology drugs.
ChemGem
An intratumoral gemcitabine depot combining the ChemoGell platform with the standard-of-care drug gemcitabine to treat pancreatic cancer (PDAC).
Services
Licensing of the injectable depot platform and support for tech transfer to CMOs or hospital pharmacies for sterile injectable production.
Reformulation services to improve solubility, stability and localized delivery of novel or generic oncology drug candidates, including feasibility and advanced development.
Conduct or support preclinical efficacy studies in PDX/xenograft models and provide analytical readouts including drug distribution, PK/PD, and proliferation biomarkers.
Licensing of the injectable depot platform and support for tech transfer to CMOs or hospital pharmacies for sterile injectable production.
Reformulation services to improve solubility, stability and localized delivery of novel or generic oncology drug candidates, including feasibility and advanced development.
Conduct or support preclinical efficacy studies in PDX/xenograft models and provide analytical readouts including drug distribution, PK/PD, and proliferation biomarkers.
Expertise Areas
- Localized drug delivery
- Hydrogel biomaterials for sustained release
- Controlled-release oncology formulation development
- Preclinical oncology models (PDX and murine xenografts)
Key Technologies
- Thermo-reversible bioerodible hydrogels
- In situ-forming injectable depots
- Sustained-release formulation design
- Pharma-grade excipient-based aqueous compounding
News & Updates
OncoLize achieved a 100% survival rate in mice with pancreatic tumors using its ChemGemTM product, in collaboration with Leiden University Medical Center. The product delivers Gemcitabine directly into tumors, reducing growth and extending survival without adverse effects.
Leiden-based Dutch start-up OncoLize received SME status from the European Medicinal Agency to accelerate clinical trials for pancreatic cancer treatment.
OncoLize achieved a 100% survival rate in mice with pancreatic tumors using its ChemGemTM product, in collaboration with Leiden University Medical Center. The product delivers Gemcitabine directly into tumors, reducing growth and extending survival without adverse effects.
Leiden-based Dutch start-up OncoLize received SME status from the European Medicinal Agency to accelerate clinical trials for pancreatic cancer treatment.